HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Depot-glucagon in the treatment of McArdle's disease.

Abstract
Glucagon has been reported to improve exercise tolerance in some patients with myophosphorylase deficiency (McArdle's disease) but a placebo effect was not excluded in previous trials. A single-blind controlled trial of glucagon in a patient with myophosphorylase deficiency is described. Although an improved exercise endurance of the forearm muscles was demonstrated with both short-acting and depot-glucagon, this was not statistically significant when compared with placebo or no treatment.
AuthorsT J Day, F L Mastaglia
JournalAustralian and New Zealand journal of medicine (Aust N Z J Med) Vol. 15 Issue 6 Pg. 748-50 (Dec 1985) ISSN: 0004-8291 [Print] Australia
PMID3869441 (Publication Type: Case Reports, Clinical Trial, Controlled Clinical Trial, Journal Article)
Chemical References
  • Delayed-Action Preparations
  • Glucagon
Topics
  • Adult
  • Delayed-Action Preparations
  • Female
  • Glucagon (administration & dosage, therapeutic use)
  • Glycogen Storage Disease (drug therapy)
  • Glycogen Storage Disease Type V (drug therapy)
  • Humans
  • Muscles (physiology)
  • Physical Endurance (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: